| - |
Magnesium Aspartate Dihydrate |
Magnaspartate® |
For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years. |
Rapid Review Complete |
14th May 2019 |
 |
| - |
Mannitol Dry Powder |
Bronchitol® |
Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF) |
Assessment Process Complete |
29th April 2019 |
|
| 22069 |
Maribavir |
Livtencity® |
For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant. |
Rapid Review Complete |
14th March 2024 |
|
| 23028 |
Mavacamten |
Camzyos® |
Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. |
NCPE assessment ongoing |
19th December 2024 |
|
| - |
Melatonin |
Circadin® |
Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia. |
Full HTA Assessment |
21st October 2008 |
|
| 22048 |
Melatonin |
Slenyto® |
For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. |
Rapid Review Complete |
9th August 2022 |
|
| 23067 |
Melphalan flufenamide |
Pepaxti® |
Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. |
Rapid Review Complete |
15th December 2023 |
|
| - |
Mepolizumab |
Nucala® |
Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. |
Assessment Process Complete |
1st March 2017 |
|
| - |
Mepolizumab |
Nucala® |
Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over. |
Rapid Review Complete |
5th November 2019 |
|
| 20007 |
Meropenem/vaborbactam |
Vaborem® |
Is indicated for the treatment of the above infections in adults. |
Rapid Review Complete |
2nd April 2020 |
|
| - |
Methoxyflurane |
Penthrox® |
For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses. |
Rapid Review Complete |
18th December 2015 |
|
| 19049 |
Methyl aminolevulinate |
Metvix® |
For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate. |
Rapid Review Complete |
18th December 2019 |
|
| - |
Midostaurin |
Rydapt® |
Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. |
Assessment Process Complete |
5th December 2019 |
|
| - |
Midostaurin |
Rydapt® |
Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). |
Suspended |
16th October 2018 |
|
| - |
Mifamurtide |
Mepact® |
For the treatment of osteosarcoma. |
Rapid Review Complete |
13th July 2010 |
|
| - |
Migalastat |
Galafold® |
For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. |
Assessment Process Complete |
1st June 2017 |
|
| - |
Mirabegron |
Betmiga® |
Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. |
Rapid Review Complete |
12th March 2013 |
|
| 23040 |
Mirikizumab |
Omvoh® |
Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. |
Rapid Review Complete |
24th August 2023 |
|
| - |
Modified Release Hydrocortisone |
Plenadren® |
For the treatment of adrenal insufficiency in adults. |
Assessment process complete |
1st January 2018 |
|
| 20061 |
Mogamulizumab |
Poteligeo® |
For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21060 |
Molnupiravir |
Lagevrio® |
For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
Rapid Review Complete |
24th December 2021 |
|
| 24002 |
Momelotinib |
Omjjara® |
Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. |
Rapid Review Complete |
22nd February 2024 |
|
| 21051 |
Mometasone furoate plus olopatadine |
Ryaltris® |
Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. |
Rapid Review Complete |
22nd December 2021 |
|
| 23023 |
Mosunetuzumab |
Lunsumio® |
Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. |
Awaiting response from Applicant |
11th December 2024 |
|
| - |
Nab-paclitaxel |
Abraxane® |
In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas. |
Assessment Process Complete |
5th September 2014 |
|
| - |
Nalmefene |
Selincro® |
Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification. |
Assessment Process Complete |
8th April 2014 |
|
| - |
Naloxegel |
Moventig® |
Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). |
Rapid Review Complete |
13th April 2015 |
|
| 20019 |
Naloxone |
Nyxoid® |
Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care. |
Rapid Review Complete |
12th May 2020 |
|
| - |
Naltrexone / bupropion |
Mysimba® |
Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities. |
Assessment Process Complete |
9th May 2018 |
|
| - |
Natalizumab |
Tysabri® |
For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated. |
Full HTA Assessment |
27th April 2007 |
|
| - |
Nepafenac |
Nevanac® |
For the prevention and treatment of postoperative pain and inflammation associated with cataract surgery. |
Rapid Review Complete |
27th June 2011 |
|
| 19057 |
Neratinib |
Nerlynx® |
For the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. |
Assessment Process Complete |
12th May 2021 |
|
| 23076 |
Netarsudil-latanoprost |
Roclanda® |
Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction. |
Rapid Review Complete |
5th June 2024 |
|
| - |
Netupitant/palonosetron |
Akynzeo® |
For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. |
Rapid Review Complete |
13th October 2015 |
|
| - |
Nilotinib CML resistant/intolerant to imatinib |
Tasigna® |
For the treatment of chronic phase CML. |
Full HTA Assessment |
25th February 2008 |
|
| - |
Nilotinib |
Tasigna® |
For the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML. |
Rapid Review Complete |
22nd October 2010 |
|
| - |
Nintedanib |
Ofev® |
Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). |
Assessment Process Complete |
22nd February 2016 |
|
| 20034 |
Nintedanib |
Ofev® |
For the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults. |
Assessment Process Complete |
24th June 2021 |
|
| - |
Nintedanib |
Vargatef® |
Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. |
Assessment Process Complete |
25th March 2016 |
|
| 21004 |
Niraparib |
Zejula® |
Is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
NCPE Assessment Process Complete |
26th September 2022 |
|
| - |
Niraparib |
Zejula® |
Is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. |
Assessment Process Complete |
14th August 2019 |
|
| 23032 |
Niraparib in combination with abiraterone acetate |
Akeega® |
Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. |
Rapid Review Complete |
20th October 2023 |
|
| 22014 |
Nirmatrelvir/Ritonavir |
Paxlovid® |
Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. |
NCPE Assessment Process Complete |
20th June 2024 |
|
| - |
Nivolumab |
Opdivo® |
As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. |
Assessment Process Complete |
17th October 2019 |
|
| 20057 |
Nivolumab |
Opdivo® |
As monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy. |
Rapid Review Complete |
13th January 2021 |
|
| 21043 |
Nivolumab |
Opdivo® |
Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| 21049 |
Nivolumab |
Opdivo® |
Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5. |
NCPE Assessment Process Complete |
11th July 2023 |
|
| - |
Nivolumab |
Opdivo® |
Is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults |
Assessment Process Complete |
28th March 2017 |
|
| - |
Nivolumab |
Opdivo® |
As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin. |
Rapid Review Complete |
18th January 2017 |
|
| - |
Nivolumab |
Opdivo® |
For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. |
Rapid Review Complete |
30th May 2017 |
|
